A study from the Association of the British Pharmaceutical Industry (ABPI) published this week in the peer-review journal Current Medical Research and Opinion (CMRO) suggests that transparency amongst industry-sponsored clinical trials is continuing to improve, with results of 90% of trials on all new medicines approved by the European Medicines Authority (EMA) in 2012 disclosed within a 12-month timeframe.
Key findings of the study show that of the 340 industry-sponsored trials (completed before the end of January 2014) associated with all 23 new medicines approved by the EMA in 2012:
- 307 or 90% had results disclosed on a registry or in scientific literature within 12 months of first regulatory approval or trial completion, and
- 312 or 92% had results disclosed by the end of the study at 31 July 2014
A press release from the ABPI about this study can be found here.
Ryan co-runs Aspire Scientific, a dynamic, forward-thinking medical writing agency. Ryan has a passion for innovation, science and ethical communication.